Vaccination with a DNA Vaccine Coding for Perforin-Like Protein 1 and MIC6 Induces Significant Protective Immunity against Toxoplasma gondii

ABSTRACT Host cell invasion by Toxoplasma gondii is tightly related to microneme protein 6 (MIC6) and T. gondii perforin-like protein 1 (TgPLP1). In this study, we constructed a DNA vaccine expressing a TgPLP1/MIC6 fusion protein using the pIRESneo vector, and we evaluated the immune response induced by this vaccine in Kunming mice. Levels of IgG antibody, gamma interferon (IFN-γ), interleukin 2 (IL-2), IL-12, IL-4, and IL-10 were examined. Five mice were chosen randomly from every group (vaccinated groups or the nonvaccinated control group) and were challenged intragastrically with 80 cysts of T. gondii strain PRU (genotype II) in order to observe mortality daily. To analyze protection against a less-virulent challenge, eight mice of each group were orally infected with 20 cysts of strain PRU at the 14th day after the last immunization. The brain parasite load was evaluated 6 weeks after infection. The results demonstrated that immunization with pIRESneo/MIC6/PLP1 resulted in the lowest brain cyst count and prolonged the survival time of immunized mice. The levels of Toxoplasma-specific IgG, IFN-γ, IL-2, and IL-12 increased significantly, and the numbers of cysts in brains decreased more obviously, in the group immunized with plasmid pIRESneo/MIC6/PLP1 than in the other groups (P < 0.05). Compared with pIRESneo/MIC6/PLP1, coimmunization with pIRESneo/MIC6/PLP1 and adjuvant murine IL-18 promoted cellular and humoral immune responses but did not contribute significantly to cyst reduction (65.43% versus 61.60%) or the survival of immunized mice (45.0 ± 2.9 days versus 42.8 ± 2.9 days) (P > 0.05). Furthermore, the study also showed that the immune efficacy induced by pIRESneo/MIC6/PLP1 was better than that induced by pVAX/PLP1 or pVAX/MIC6 alone.

[1]  M. Liao,et al.  Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18. , 2011, Vaccine.

[2]  Zi-Guo Yuan,et al.  Toxoplasma gondii: protective immunity against experimental toxoplasmosis induced by a DNA vaccine encoding the perforin-like protein 1. , 2011, Experimental parasitology.

[3]  Zi-Guo Yuan,et al.  Protective Immunity Induced by Toxoplasma gondii Rhoptry Protein 16 against Toxoplasmosis in Mice , 2010, Clinical and Vaccine Immunology.

[4]  Hongwei Gao,et al.  The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18. , 2010, Research in veterinary science.

[5]  Zi-Guo Yuan,et al.  Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis , 2010, Parasitology Research.

[6]  Zi-Guo Yuan,et al.  Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice. , 2009, Vaccine.

[7]  F. Zou,et al.  Seroprevalence of Toxoplasma gondii in pigs in southwestern China. , 2009, Parasitology international.

[8]  Ming Gan,et al.  MIC6 associates with aldolase in host cell invasion by Toxoplasma gondii , 2009, Parasitology Research.

[9]  Lin Shi,et al.  Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice , 2009, Parasitology Research.

[10]  Sandeep Ravindran,et al.  Rapid Membrane Disruption by a Perforin-Like Protein Facilitates Parasite Exit from Host Cells , 2009, Science.

[11]  L. Shang,et al.  Enhancement by IL-18 of the protective effect of a Schistosoma japonicum 26kDa GST plasmid DNA vaccine in mice. , 2008, Vaccine.

[12]  M. Igarashi,et al.  Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential. , 2007, Experimental parasitology.

[13]  Y. Li,et al.  Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice , 2007, Parasitology Research.

[14]  D. Hill,et al.  PREVALENCE OF VIABLE TOXOPLASMA GONDII IN BEEF, CHICKEN, AND PORK FROM RETAIL MEAT STORES IN THE UNITED STATES: RISK ASSESSMENT TO CONSUMERS , 2005, The Journal of parasitology.

[15]  Kami Kim,et al.  Toxoplasma gondii: the model apicomplexan. , 2004, International journal for parasitology.

[16]  J. Lannes-Vieira,et al.  Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. , 2003, Vaccine.

[17]  L. Weiss,et al.  Toxoplasma gondii: from animals to humans. , 2000, International journal for parasitology.

[18]  M. Caligiuri,et al.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. , 1999, Journal of immunology.

[19]  L. Babiuk,et al.  Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. , 1997, Vaccine.

[20]  M. Su,et al.  Activation of Interferon-γ Inducing Factor Mediated by Interleukin-1β Converting Enzyme , 1997, Science.

[21]  H. Okamura,et al.  A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock , 1995, Infection and immunity.

[22]  J. Dubey,et al.  National seroprevalence of Toxoplasma gondii in pigs. , 1991, The Journal of parasitology.

[23]  V. Letscher-Bru,et al.  Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice. , 1998, Infection and immunity.

[24]  M Kurimoto,et al.  Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. , 1997, Science.

[25]  C. Roberts,et al.  Immunological control of Toxoplasma gondii and appropriate vaccine design. , 1996, Current topics in microbiology and immunology.

[26]  F. Araújo.  Immunization against Toxoplasma gondii. , 1994, Parasitology today.

[27]  S. Romagnani.  Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? , 1992, Immunology today.